Advances in mechanisms of allergy and clinical immunology in 2012 - 27/02/13
, Marc E. Rothenberg, MD, PhD b, Joshua A. Boyce, MD c, Fred Finkelman, PhD b
Corresponding author: Bruce S. Bochner, MD, Division of Allergy and Clinical Immunology, Johns Hopkins Asthma and Allergy Center, 5501 Hopkins Bayview Circle, Rm 2B.71, Baltimore, MD 21224-6821.Abstract |
Manuscripts published in the “Mechanisms of allergy and clinical immunology” section of the Journal of Allergy and Clinical Immunology during 2012 enhanced our knowledge of the involvement of cytokines and other mediators in allergic disorders and described novel approaches for understanding mechanisms of allergic and immunologic diseases. Also published were articles focused on mechanisms of allergen-specific immunotherapy and the development of novel antiallergic treatments, as well as strategies to achieve tolerance to allergens. The highlights of these studies and their potential clinical implications are summarized in this review.
Le texte complet de cet article est disponible en PDF.Key words : Dendritic cells, cytokines, immunotherapy, mast cell, basophil, eosinophil, T cells, regulatory T cells
Abbreviations used : AHR, CIITA, CRTH2, CysLT, DC, EMT, EPF, Foxp3, HDE, HDM, IRAK-M, MITF, MSC, ⍺-MSH, NLRP3, OVA, OX40L, PAR, PG, SLIT, SPT, TFE3, TLR, Treg, TSLP
Plan
| Disclosure of potential conflict of interest: B. S. Bochner is a Scientific Advisory Board member for Allakos and Merck; has consultancy arrangements with TEVA, Sanofi-Aventis, United States Diagnostic Standards, Medicis, Pharmacyclics, Hoffman–La Roche, and Tarsa Therapeutics; is employed by Johns Hopkins University; has received one or more grants from or has one or more grants pending with the National Institutes of Health (NIH) and the Dana Foundation; has received royalties from Elsevier and from UpToDate; and owns stock/stock options in Allakos and in Glycomimetics. M. E. Rothenberg is a Board member for the International Eosinophil Society and for the American Partnership for Eosinophilic Disorders; serves as Consultant and Director of the Scientific Advisory Board of, owns stock/stock options in, and has received one or more payments for travel/accommodations/meeting expenses from Immune Pharm; has received one or more grants from or has one or more grants pending with the NIH and the Department of Defense (DOD); is the inventor of patents that are owned by CCHMC; and has received royalties from Teva Pharmaceuticals. J. A. Boyce has been supported by one or more grants from, has received one or more consulting fees or honoraria from, and has received one or more payments for lecturing from or is on the speakers’ bureau for Merck and has consultancy arrangements with Calcimedica. F. Finkelman has received one or more grants from or has one or more grants pending with the NIH, the Veterans Administration, and the DOD and has a pending patent for desensitization. |
Vol 131 - N° 3
P. 661-667 - mars 2013 Retour au numéro
Article précédent
- Combined immunodeficiency: The Middle East experience
- Waleed Al-Herz, Hamoud Al-Mousa
- Advances in environmental and occupational disorders in 2012
- David B. Peden, Robert K. Bush
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?